Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants

Laboratory Investigation

Volumn 84, Issue 5, 2004, Pages 545-552

  Miller, Sean R ^a   Sekijima, Yoshiki ^a   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Amyloidosis; Familial amyloid polyneuropathy; Native state stabilization; NSAIDs; Transthyretin

Indexed keywords

2 [(3,5 DICHLOROPHENYL)AMINO]BENZOIC ACID; AMYLOID; DICLOFENAC; DICLOFENAC DERIVATIVE; DIFLUNISAL; FLUFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PREALBUMIN; TETRAMER; UNCLASSIFIED DRUG; UREA;

ARTICLE; CIRCULAR DICHROISM; DENATURATION; DISSOCIATION; DRUG STRUCTURE; FAMILIAL AMYLOID POLYNEUROPATHY; FLUORESCENCE; HETEROZYGOTE; HUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; THERMODYNAMICS; WILD TYPE; AMYLOIDOSIS; CHEMISTRY; DRUG STABILITY; GENETIC VARIABILITY; GENETICS; IN VITRO STUDY; KINETICS; METABOLISM; PROTEIN QUATERNARY STRUCTURE;

AMYLOIDOSIS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG STABILITY; HUMANS; KINETICS; PREALBUMIN; PROTEIN FOLDING; PROTEIN STRUCTURE, QUATERNARY; VARIATION (GENETICS);

EID: 2942599707     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700059     Document Type: Article

References (42)

1. Sipe JD. Amyloidosis. Annu Rev Biochem 1992;61:947-975.
2. Sipe JD. Amyloidosis. Crit Rev Clin Lab Sci 1994;31:325-354.
3. Tan SY, Pepys MB, Amyloidosis. Histopathology 1994;25:403-414.
4. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992;31:8654-8660.
5. Kelly JW, Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 1996;6:11-17.
6. Kelly JW, Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure 1997;5:595-600.
7. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998;8:101-106.
8. Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996;35:6470-6482.
9. Bartalena L, Robbins J. Thyroid hormone transport proteins. Clin Lab Med 1993;13:583-598.
10. Blake CC, Geisow MJ, Oatley SJ, et al. Structure of prealbumin: secondary, tertiary and quarternary interactions determined by Fourier refinement at 1.8 Å, J Mol Biol 1978;121:339-356.
11. Monaco HL. The transthyretin-retinol-binding protein complex. Biochim Biophys Acta 2000;1482:65-72.
12. Jiang X, Smith CS, Petrassi HM. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 2001;40:11442-11452.
13. Cornwell III GC, Sletten K, Johansson B, Westermark P. Evidence that the amyloid fibril protein in senile systemic amyloidosis is derived from normal prealbumin. Biochem Biophys Res Commun 1988;154:648-653.
14. Saraiva MJ, Birken S, Costa PP, et al. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. J Clin Inv 1984;74:104-119.
15. Westermark P, Sletten K, Johansson B, et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87:2843-2845.
16. Cornwell III GG, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983;75:618-623.
17. Wallace MR, Dwulet FE, Conneally PM, et al. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Inv 1986;78:6-12.
18. Jacobson DR. Amyloidosis, transthyretin-related. E-Medicine. 2002;http://www.emedicine.com/med/ topic3365.htm.
19. Benson MD, Uemichi T. Transthyretin amyloidosis. Amyloid 1996;3:44-56.
20. Connors LH, Richardson AM, Théberge R, et al. Tabulation of transthyretin (TTR) variants as of 1/1/ 2000. Amyloid 2000;7:54-69.
21. Nichols WC, Liepnieks JJ, McKusick VA, et al. Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II and genotyping by allele-specific enzymatic amplification. Genomics 1989;5:535-540.
22. Jacobson DR, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-473.
23. Hammarström P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713-716.
24. Klabunde T, Petrassi HM, Oza VB, et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000;7:312-321.
25. Oza VB, Smith C, Raman P, et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem 2002;45:321-332.
26. Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov 2002;1:267-275.
27. Miroy GJ, Lai Z, Lashuel HA, et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 1996;93:15051-15056.
28. Peterson SA, Klabunde T, Lashuel HA, et al. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci USA 1998;95:12956-12960.
29. Purkey HE, Dorrell MI, Kelly JW. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci USA 2001;98:5566-5571.
30. Steelman SL, Cirillo VJ, Tempero KF. The chemistry, pharmacology and clinical pharmacology of diflunisal. Curr Med Res Opin 1978;5:506-514.
31. Lashuel HA, Wurth C, Woo L, Kelly JW. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 1999;38:13560-13573.
32. Hammarström P, Jiang X, Deechongkit S, et al. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry 2001;40:11453-11459.
33. Hammarström P, Jiang X, Hurshman AR, et al. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002;99:16427-16432.
34. Coelho T, Carvalho M, Saraiva MJ, et al. Familial amyloidotic polyneuropathy and other transthyretin related disorders. Second International Symposium. J Rheumatol 1993;20:179.
35. Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001;293:2459-2462.
36. Skinner M, Lewis WD, Jones LA, et al. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 1994;120:133-134.
37. Holmgren G, Haettner E, Nordenson I, et al. Homozygosity for the transthyretin-met30-gene in two Swedish sibs with familial amyloidotic polyneuropathy. Clin Genet 1988;34:333-338.
38. Sandgren O, Holmgren G, Lundgren E. Vitreous amyloidosis associated with homozygosity for the transthyretin methionine-30 gene. Arch Ophthalmol 1990;108:1584-1586.
39. Skare J, et al. Homozygosity for the met30 transthyretin gene in a Turkish kindred with familial amyloidotic polyneuropathy. Hum Genet 1990;86:89-90.
40. Holmgren G, et al. Homozygosity for the transthyretin-Met30-gene in seven individuals with familial amyloidosis with polyneuropathy detected by restriction enzyme analysis of amplified genomic DNA sequences. Clin Genet 1992;41:39-41.
41. Yoshinaga T, Nakazato M, Ikeda S, et al. Homozygosity for the transthyretin-Met30 gene in three Japanese siblings with type I familial amyloidotic polyneuropathy. Neurology 1992;42:2045-2047.
42. Yoshioka A, et al. A case of familial amyloid polyneuropathy homozygous for the transthyretin Val30Met gene with motor-dominant sensorimotor polyneuropathy and unusual sural nerve pathological findings. Arch Neurol 2001;58:1914-1918.